Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -6.14% is 915% below its 5-year average of 0.75%, near the low end of its 5-year range (-8.59%–4.01%).
As of the fiscal period ended Wednesday, December 31, 2025. 168.12% below its 12-month average of -2.29%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
-6.14%
RETURN ON ASSETS (ROA) AVG TTM
-2.29%
RETURN ON ASSETS (ROA) AVG 3Y
0.04%
RETURN ON ASSETS (ROA) AVG 5Y
0.75%
RETURN ON ASSETS (ROA) AVG 10Y
2.01%
RETURN ON ASSETS (ROA) AVG 15Y
3.33%
RETURN ON ASSETS (ROA) AVG 20Y
3.73%
CURRENT VS TTM AVG
-168.12%
CURRENT VS 3Y AVG
-14547.06%
CURRENT VS 5Y AVG
-915.04%
CURRENT VS 10Y AVG
-406.17%
CURRENT VS 15Y AVG
-284.20%
CURRENT VS 20Y AVG
-264.42%
SECTOR MEDIAN · HEALTHCARE
4.97%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-223.54%
vs the sector median at left
Centene Corp.
Market Cap
$30.74B
Return on Assets (ROA)
-6.14%
TTM Avg
-2.29%
3Y Avg
0.04%
5Y Avg
0.75%
Market Cap
$30.72B
Return on Assets (ROA)
4.27%
TTM Avg
5.83%
3Y Avg
5.87%
5Y Avg
14.86%
Market Cap
$30.60B
Return on Assets (ROA)
17.30%
TTM Avg
16.00%
3Y Avg
15.15%
5Y Avg
14.03%
Market Cap
$31.49B
Return on Assets (ROA)
15.49%
TTM Avg
11.04%
3Y Avg
9.26%
5Y Avg
8.83%
Market Cap
$32.40B
Return on Assets (ROA)
17.44%
TTM Avg
17.37%
3Y Avg
16.33%
5Y Avg
15.33%
Market Cap
$28.62B
Return on Assets (ROA)
24.67%
TTM Avg
25.02%
3Y Avg
24.63%
5Y Avg
23.85%
Market Cap
$33.22B
Return on Assets (ROA)
2.47%
TTM Avg
3.17%
3Y Avg
1.75%
5Y Avg
1.75%
Market Cap
$27.50B
Return on Assets (ROA)
14.54%
TTM Avg
-0.12%
3Y Avg
-10.91%
5Y Avg
-15.37%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Centene Corp. (CNC) | $30.74B | -6.14% | -2.29% | 0.04% | 0.75% |
| GE HealthCare Technologies Inc. (GEHC)vs › | $30.72B | 4.27% | 5.83% | 5.87% | 14.86% |
| ResMed Inc. (RMD)vs › | $30.60B | 17.30% | 16.00% | 15.15% | 14.03% |
| Biogen Inc. (BIIB)vs › | $29.99B | 2.83% | 5.11% | 6.74% | 8.29% |
| DexCom, Inc. (DXCM)vs › | $31.49B | 15.49% | 11.04% | 9.26% | 8.83% |
| Zoetis Inc. (ZTS)vs › | $32.40B | 17.44% | 17.37% | 16.33% | 15.33% |
| Mettler-Toledo International Inc. (MTD)vs › | $28.62B | 24.67% | 25.02% | 24.63% | 23.85% |
| Medline Inc. (MDLN)vs › | $33.22B | 2.47% | 3.17% | 1.75% | 1.75% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $27.50B | 14.54% | -0.12% | -10.91% | -15.37% |
| Quest Diagnostics Incorporated (DGX)vs › | $25.72B | 6.27% | 5.75% | 6.24% | 8.30% |
ROA
-6.1%
ROE
-22.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -8.59% |
| 2024-12-31 | 4.01% |
| 2023-12-31 | 3.19% |
| 2022-12-31 | 1.56% |
| 2021-12-31 | 1.72% |
| 2020-12-31 | 2.63% |
| 2019-12-31 | 3.22% |
| 2018-12-31 | 2.91% |
| 2017-12-31 | 3.79% |
| 2016-12-31 | 2.78% |
| 2015-12-31 | 4.84% |
| 2014-12-31 | 4.64% |
| 2013-12-31 | 4.68% |
| 2012-12-31 | 0.07% |
| 2011-12-31 | 5.08% |
| 2010-12-31 | 4.88% |
| 2009-12-31 | 4.91% |
| 2008-12-31 | 5.75% |
| 2007-12-31 | 6.56% |
| 2006-12-31 | -4.87% |
| 2005-12-31 | 8.33% |
| 2004-12-31 | 8.39% |
| 2003-12-31 | 9.17% |
| 2002-12-31 | 12.18% |
| 2001-12-31 | 9.82% |
| 2000-12-31 | 11.71% |
| 1999-12-31 | -18.03% |
| 1998-12-31 | 0.00% |
